Quantity of qualified sufferers: CDEC discussed the uncertainty in the quantity of sufferers with moderately extreme to significant hemophilia B in Canada eligible for etranacogene dezaparvovec. Medical authorities consulted by CADTH indicated that some individuals that are classified as getting gentle or average disorder could have a intense bleeding phenotype, https://hemgenix41604.blogocial.com/everything-about-hemgenix-71528773